Shandong Sito Bio-technology Co Ltd
Shandong Sito Bio-technology Co., Ltd. researches, develops, and produces steroid biomedicine intermediates. Its products include 9a-hydroxyandrost, 17a-hydroxyprogesterone, 17a-hydroxy progesterone derivatives, anecort acetate, neomycin sulfate, progesterone intermediate, tylvalosin tartrate, tetraene acetate, androstenedione, bisnoralcohol, norandrostenedione, ethylene deltenone, 16ß and 16a me… Read more
Shandong Sito Bio-technology Co Ltd (300583) - Total Assets
Latest total assets as of September 2025: CN¥2.87 Billion CNY
Based on the latest financial reports, Shandong Sito Bio-technology Co Ltd (300583) holds total assets worth CN¥2.87 Billion CNY as of September 2025.
Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments.
Shandong Sito Bio-technology Co Ltd - Total Assets Trend (2012–2024)
This chart illustrates how Shandong Sito Bio-technology Co Ltd’s total assets have evolved over time, based on quarterly financial data. Explore and compare other companies by total assets.
Shandong Sito Bio-technology Co Ltd - Asset Composition Analysis
Current Asset Composition (December 2024)
Shandong Sito Bio-technology Co Ltd's total assets of CN¥2.87 Billion consist of 42.5% current assets and 57.5% non-current assets.
| Asset Category | Amount (CNY) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | CN¥0.00 | 8.5% |
| Accounts Receivable | CN¥349.75 Million | 11.6% |
| Inventory | CN¥644.88 Million | 21.3% |
| Property, Plant & Equipment | CN¥0.00 | 0.0% |
| Intangible Assets | CN¥189.15 Million | 6.3% |
| Goodwill | CN¥0.00 | 0.0% |
Asset Composition Trend (2012–2024)
This chart illustrates how Shandong Sito Bio-technology Co Ltd's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Shandong Sito Bio-technology Co Ltd's current assets represent 42.5% of total assets in 2024, a decrease from 52.7% in 2012.
- Cash Position: Cash and equivalents constituted 8.5% of total assets in 2024, up from 0.1% in 2012.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 6.0% of total assets, a decrease from 19.0% in 2012.
- Asset Diversification: The largest asset category is inventory at 21.3% of total assets.
Shandong Sito Bio-technology Co Ltd Competitors by Total Assets
Key competitors of Shandong Sito Bio-technology Co Ltd based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
MedPacto Inc
KQ:235980
|
Korea | ₩51.58 Billion |
|
2H0
F:2H0
|
Germany | €15.27 Million |
|
Shenzhen CAU Technology Co Ltd
SHE:000004
|
China | CN¥260.55 Million |
|
Pacific Shuanglin Bio pharmacy Co Ltd
SHE:000403
|
China | CN¥9.58 Billion |
|
Nanhua Bio Medicine Co Ltd
SHE:000504
|
China | CN¥841.96 Million |
|
Jiangsu Sihuan Bioengineering Co Ltd
SHE:000518
|
China | CN¥509.14 Million |
|
Chengzhi Shareholding Co Ltd
SHE:000990
|
China | CN¥27.52 Billion |
|
Hualan Biological EngineeringInc
SHE:002007
|
China | CN¥16.27 Billion |
Shandong Sito Bio-technology Co Ltd - Asset Efficiency Metrics
Asset efficiency metrics measure how effectively a company uses its assets to generate revenue and profits. These indicators help investors evaluate management's ability to deploy capital efficiently.
Asset Turnover Ratio
Measures how efficiently a company uses its assets to generate sales
Lower asset utilization - Shandong Sito Bio-technology Co Ltd generates 0.32x its asset value in annual revenue.
Return on Assets (ROA)
Measures how efficiently a company uses its assets to generate profits
Negative ROA - Shandong Sito Bio-technology Co Ltd is currently not profitable relative to its asset base.
Shandong Sito Bio-technology Co Ltd - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 1.21 | 1.38 | 1.21 |
| Quick Ratio | 0.71 | 0.67 | 0.65 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | CN¥207.07 Million | CN¥ 369.73 Million | CN¥ 201.38 Million |
Shandong Sito Bio-technology Co Ltd - Advanced Valuation Insights
This section examines the relationship between Shandong Sito Bio-technology Co Ltd's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 1.60 |
| Latest Market Cap to Assets Ratio | 0.06 |
| Asset Growth Rate (YoY) | -6.6% |
| Total Assets | CN¥3.03 Billion |
| Market Capitalization | $178.00 Million USD |
Valuation Analysis
Below Book Valuation: The market values Shandong Sito Bio-technology Co Ltd's assets below their book value (0.06 x), which may indicate investor concerns about asset quality or future growth.
Significant Asset Reduction: Shandong Sito Bio-technology Co Ltd's assets decreased by 6.6% over the past year, potentially indicating divestiture, restructuring, or challenging business conditions.
Annual Total Assets for Shandong Sito Bio-technology Co Ltd (2012–2024)
The table below shows the annual total assets of Shandong Sito Bio-technology Co Ltd from 2012 to 2024.
| Year | Total Assets | Change |
|---|---|---|
| 2024-12-31 | CN¥3.03 Billion | -6.62% |
| 2023-12-31 | CN¥3.24 Billion | +8.18% |
| 2022-12-31 | CN¥3.00 Billion | +0.86% |
| 2021-12-31 | CN¥2.97 Billion | +4.52% |
| 2020-12-31 | CN¥2.84 Billion | -4.89% |
| 2019-12-31 | CN¥2.99 Billion | +15.14% |
| 2018-12-31 | CN¥2.59 Billion | +28.15% |
| 2017-12-31 | CN¥2.02 Billion | +116.25% |
| 2016-12-31 | CN¥936.23 Million | +11.68% |
| 2015-12-31 | CN¥838.28 Million | +65.30% |
| 2014-12-31 | CN¥507.11 Million | +140.73% |
| 2013-12-31 | CN¥210.66 Million | +251.20% |
| 2012-12-31 | CN¥59.98 Million | -- |